Your account is not claimed yet. You can sign up with ORCID to claim your account.

Yonghong Li

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 7

Top Venues

Blood cancer journal

Molecular diagnosis & therapy

Quest Diagnostics Nichols Institute (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Quest Diagnostics Nichols Institute

United States

PHD

Publications

Yonghong Li, Jose Solis-Ruiz, Fei Yang, Nicola Long, Carmen H Tong, Felicitas L Lacbawan, Frederick K Racke, Richard D Press
NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia. Blood cancer journal 13 (1) (2023)
Yonghong Li, Jose Solis-Ruiz, Fei Yang, Nicola Long, Carmen H Tong, Felicitas L Lacbawan, Frederick K Racke, Richard D Press
NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia. Blood cancer journal 13 (1) (2023)
Yonghong Li, Jose Solis-Ruiz, Fei Yang, Nicola Long, Carmen H Tong, Felicitas L Lacbawan, Frederick K Racke, Richard D Press
NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia. Blood cancer journal 13 (1) (2023)
Yonghong Li, Jose Solis-Ruiz, Fei Yang, Nicola Long, Carmen H Tong, Felicitas L Lacbawan, Frederick K Racke, Richard D Press
NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia. Blood cancer journal 13 (1) (2023)
Yonghong Li, Jose Solis-Ruiz, Fei Yang, Nicola Long, Carmen H Tong, Felicitas L Lacbawan, Frederick K Racke, Richard D Press
NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia. Blood cancer journal 13 (1) (2023)
Yonghong Li, Jose Solis-Ruiz, Fei Yang, Nicola Long, Carmen H Tong, Felicitas L Lacbawan, Frederick K Racke, Richard D Press
NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia. Blood cancer journal 13 (1) (2023)
Yonghong Li, Lori A Anderson, Edward I Ginns, James J Devlin
Cost Effectiveness of Karyotyping, Chromosomal Microarray Analysis, and Targeted Next-Generation Sequencing of Patients with Unexplained Global Developmental Delay or Intellectual Disability. Molecular diagnosis & therapy 22 (1) (2018)

Yonghong Li.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Yonghong Li